LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM.
Human monocytes and neutrophils play major roles in clearing bacteria from human blood and tissues. We found that the herpes virus entry mediator (HVEM) was highly expressed in monocytes and neutrophils, and its interaction with "homologous to lymphotoxins, shows inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM/tumor necrosis factor (TNF)-related 2" (LIGHT) enhanced bactericidal activity against Listeria monocytogenes and Staphylococcus aureus. The LIGHT-HVEM interaction increased levels of phagocytosis, interleukin (IL)-8, TNF-alpha, nitric oxide (NO), and reactive oxygen species (ROS) in monocytes and neutrophils. Anti-HVEM monoclonal antibody was able to block LIGHT-induced bactericidal activity, cytokine production (IL-8 and TNF-alpha), and ROS generation. Moreover, inhibition of ROS and NO production blocked LIGHT-induced bactericidal activity. Our results indicate that the LIGHT/HVEM interaction in monocytes and neutrophils contributes to antibacterial activity.
Heo
Sook-Kyoung
SK
University of Ulsan, San 29, Mookeo-dong, Nam-ku, Ulsan, Republic of Korea.
Ju
Seong-A
SA
Lee
Sang-Chul
SC
Park
Sang-Min
SM
Choe
Suck-Young
SY
Kwon
Byungsuk
B
Kwon
Byoung S
BS
Kim
Byung-Sam
BS
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D006801:Humans; D016209:Interleukin-8 / Q000096:biosynthesis; D008089:Listeria monocytogenes / Q000187:drug effects / Q000276:immunology; D008233:Lymphotoxin-alpha / Q000037:antagonists & inhibitors / Q000276:immunology / Q000494:pharmacology*; D008565:Membrane Proteins / Q000502:physiology*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D009569:Nitric Oxide / Q000096:biosynthesis; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D017382:Reactive Oxygen Species / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors / Q000276:immunology*; D053240:Receptors, Tumor Necrosis Factor, Member 14; D011991:Receptors, Virus / Q000037:antagonists & inhibitors / Q000276:immunology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000276:immunology; D047992:TNF Receptor-Associated Factor 2 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000494:pharmacology*; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000502:physiology*; D014759:Viral Envelope Proteins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D016209:Interleukin-8; D008233:Lymphotoxin-alpha; D008565:Membrane Proteins; D017382:Reactive Oxygen Species; D018124:Receptors, Tumor Necrosis Factor; D053240:Receptors, Tumor Necrosis Factor, Member 14; D011991:Receptors, Virus; D047992:TNF Receptor-Associated Factor 2; C506028:TNFRSF14 protein, human; C505914:TNFSF14 protein, human; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D014409:Tumor Necrosis Factor-alpha; D014759:Viral Envelope Proteins; C039447:glycoprotein D, Human herpesvirus 1; D009569:Nitric Oxide